A QCM-D study of oxyntomodulin and Aib2-Oxm fibrils provides the first integrated thermodynamic-kinetic framework for peptide depot design. Aib2-Oxm fibrils dissociate faster than oxyntomodulin fibrils, predicting greater in-serum bioactivity, while release at subcutaneous temperature is…
Researchers report the first comprehensive quantitative analysis of fibril thermodynamics and kinetics for oxyntomodulin Oxm and its analogue Aib2-Oxm , using quartz crystal microbalance with dissipation QCM-D . The study, published in Langmuir , a journal of the American Chemical Society, finds that Aib2-Oxm fibrils dissociate faster than Oxm fibrils while releasing peptide substantially more slowly at subcutaneous temperature than at core physiological temperatures. The faster dissociation leads the researchers to predict greater in-serum bioactivity for Aib2-Oxm, because the release of free peptide is enhanced. The temperature contrast means that a depot injected under the skin would hold its payload at the roughly 32 °C injection site and release it more quickly from material that reaches the 37 to 42 °C core, a difference that becomes clinically acute during fever.
The technique defines what is new. Conventional aggregation assays, such as thioflavin T fluorescence or turbidity, report ensemble signals from bulk solution and have difficulty separating nucleation from elongation or following dissociation directly. QCM-D tracks both the mass and the mechanical character of a deposited layer in real time and without labels, so the growth of a fibrillar film and the release of peptide from that film can be quantified as distinct events. That separation is what allows the study to claim the first integrated thermodynamic-kinetic framework for Oxm and Aib2-Oxm fibrils: a single platform on which equilibrium solubility, elongation barriers, dissociation rates, and temperature dependence are measured consistently for two closely related peptides.
The clinical problem the study addresses is familiar to peptide scientists. Both Oxm and Aib2-Oxm have short serum half-lives because rapid enzymatic degradation clears them quickly. Fibrillar self-assembly markedly enhances the stability of both peptides, and a fibrillar suspension is in effect a solid-phase reservoir of the drug. But a fibril is only useful as a medicine if it returns peptide to solution on a therapeutic timescale, and that return is governed by the dissociation kinetics the study measures. The framework is intended to supply engineering principles for long-acting, protease-resistant peptide depots for obesity and type 2 diabetes.
Peptide drug development normally treats aggregation as a liability to be suppressed during manufacture and storage. This work inverts that logic: the fibrillar form is the product, and the design variables are the equilibrium solubility of the peptide, the height of the barrier to joining the fibril, the rate of leaving it, and the temperature profile of the injection site. The last of these carries immediate practical weight, because subcutaneous tissue is cooler than the core and the same material will behave differently in the two compartments.
Both Oxm and Aib2-Oxm formed fibrils under the experimental conditions studied. The central thermodynamic quantity is the equilibrium free-peptide concentration , the concentration of soluble peptide that coexists with the fibrillar state. When the soluble concentration exceeds the equilibrium solubility, the solution is supersaturated with respect to the fibril, and incorporating additional peptide into the fibril lowers the system's free energy. The greater the ratio of soluble to equilibrium concentration, the stronger the thermodynamic drive to assemble.
Oxm fibrils showed a lower equilibrium free-peptide concentration than Aib2-Oxm fibrils, consistent with greater apparent thermodynamic stability. Two further observations supported the same ordering: Oxm fibrils showed greater apparent lateral fibril association, and secondary-structure trends provided additional evidence of a more stable fibril. The word "apparent" is deliberate. Each of these measurements integrates many microscopic events, so the stability ranking is empirical and convergent rather than reducible to a single structural quantity.
The kinetics ran in the opposite direction from the thermodynamics. Oxm peptides elongated faster on preformed fibril seeds. Aib2-Oxm elongation, by contrast, involved a larger apparent activation barrier for conformational incorporation into the fibrillar state, and a larger activation energy for peptide unfolding slowed Aib2-Oxm fibrillation relative to Oxm nucleation and elongation. Yet Aib2-Oxm fibrils dissociated faster than Oxm fibrils. There is no paradox in this combination. The equilibrium free-peptide concentration reports the net balance of addition and removal; the incorporation barrier reports only the addition step; the dissociation rate reports the barrier from the fibril back to solution. A fibril contact can be costly to form and easy to break. Oxm builds the thermodynamically favored fibril; Aib2-Oxm builds the kinetically fragile one. The dissociation asymmetry is the basis of the study's pharmacological prediction: faster dissociation should yield greater in-serum bioactivity through enhanced peptide release.
Aib2-Oxm assembly followed classical Arrhenius behavior across temperature, peptide concentration, and seed size, the same three variables across which its fibrillation and dissociation were examined. Fibrillation rates doubled between 23 °C and 37 °C. Peptide release increased with temperature and was substantially slower at 32 °C, the subcutaneous condition, than across the 37 to 42 °C core physiological range. The clean Arrhenius dependence across three independent variables indicates that a single rate-limiting barrier dominated assembly throughout the studied range.
The study was an experimental biophysical investigation, not a clinical trial. No human or animal population was studied, and the paper reports no sample size, no study duration, and no statistical detail. The endpoints were:
A quartz crystal microbalance with dissipation monitors a piezoelectric quartz sensor as material adsorbs to it. Frequency shifts report added mass. The dissipation signal reports how much energy the adsorbed layer absorbs as the crystal rings down: a thin, rigid deposit dissipates little energy, while a soft, hydrated, loosely packed layer dissipates much more. The two channels together distinguish a dense fibrillar film from an amorphous or swollen deposit, and they make it possible to follow peptide deposition and release in real time without labels. Label-free operation matters for aggregation studies because added dyes or labels can themselves change nucleation and growth.
The design extracts thermodynamic preferences from the equilibrium free-peptide concentration and kinetic parameters from the temperature dependence of the measured rates. The extracted quantities are empirical parameters, not elementary steps: each "activation barrier" lumps diffusion to the surface, desolvation, conformational rearrangement, docking, and hydrogen-bond zippering into a single number. That is acceptable for engineering purposes if the conditions are stated, but it is a reason to treat the quoted barriers as comparative rather than literal.
What the method cannot do is as important as what it can. QCM-D reports events at a sensor surface under laboratory solution conditions, not fibrils suspended in bulk solution, and the surface itself can influence nucleation and packing. It does not measure bioactivity, protease exposure in blood, or the pharmacokinetics of an injected peptide. The absence of stated statistical detail is a genuine limitation: the equilibrium concentrations, activation barriers, and temperature coefficients are parameters fitted to data, and for a framework meant to guide depot design, the uncertainty on those fitted values matters as much as the values themselves.
Amyloid-type assembly is nucleation-dependent, and that fact organizes the seeding results. Monomers associate into a marginal cluster; below a critical size the cluster tends to dissolve, and above it growth is favored. The consequence is a lag phase, a period during which little aggregated material is detectable before elongation accelerates. The lag phase is why endpoint measurements of fibrillation are hard to interpret: identical amounts of aggregate after a fixed time can conceal very different nucleation and elongation histories. Preformed fibril fragments, or seeds, bypass nucleation entirely by supplying existing ends onto which soluble peptide can add.
In a seeded experiment, the measured rate reflects the cost of adding a soluble chain to an existing fibril end and of whatever conformational rearrangement the chain must undergo before it packs into the fibril. Oxm paid that cost more readily: Oxm peptides elongated faster on preformed fibril seeds. Aib2-Oxm added to seeds more slowly because its elongation carried a larger apparent activation barrier for conformational incorporation. The seed experiment therefore isolates the growth step that bulk measurements cannot resolve.
The seeding result has a direct formulation consequence. In a fibril-based product, seed content is a process variable, not an accident. Deliberate seeding could standardize fibril morphology and, with it, the release profile. Inadvertent seeding, from container surfaces, transfer pumps, or freeze-thaw cycles, would change the product's assembly state without any label on the vial. Because Aib2-Oxm's larger elongation barrier dampens seeded growth, its assembly is more tolerant of stray fragments than Oxm's. The same ends that drive elongation are also the sites from which monomers leave, so the number of ends per unit mass couples release rate to particle size. Particle size distribution is therefore a release-rate specification, not a cosmetic one.
Oxyntomodulin is a proglucagon-derived peptide hormone that activates both the glucagon-like peptide-1 receptor and the glucagon receptor. That dual agonism is the basis of current interest in obesity and type 2 diabetes because it couples appetite suppression with increased energy expenditure, but its therapeutic use has been constrained by the rapid enzymatic degradation that clears it from serum. The point of a fibrillar depot is to change the delivery problem: hold the peptide in a protected, aggregated state and release it slowly enough that serum levels remain meaningful.
Fibrillar self-assembly protects the peptide through the cross-beta architecture common to amyloid-type fibrils. Backbone hydrogen bonds run along the fibril axis, each monomer adopts an extended conformation, and the beta-sheets stack so that the backbone sites recognized by proteases are buried in the packed interior. That packing is why fibrillar self-assembly markedly enhances the stability of both Oxm and Aib2-Oxm. The cost is that the peptide cannot signal while in the fibril. It must leave the packed state and refold into its solution conformation before it can engage a receptor, which makes the dissociation rate the link between the depot and the pharmacology.
The equilibrium free-peptide concentration is the hinge of the framework. A fibril can be treated as a solid phase in equilibrium with soluble peptide. While fibrillar material remains, dissociation tends to hold the local soluble concentration near the equilibrium value, and the body's clearance of free peptide is what drives further dissociation; the reservoir is exhausted only when the fibrillar phase is depleted. The greater apparent lateral fibril…
Peptides referenced: Glucagon, GLP-1.
Related reading: GLP-1 therapy tied to rapid gains in mood and sleep in obesity, GLP-1 Retinopathy Meta-Analysis Finds No Class-Wide Risk Signal, Circular RNA peptide drives osimertinib resistance in NSCLC via NT5C2, FDA's Compounded GLP-1 Warning Letters and the Embody Telehealth Model.